Lenzetto (Estradiol)

Estradiol in Lenzetto penetrates the skin and enters the bloodstream, where it binds to estrogen receptors (ERα and ERβ). The hormone‑receptor complex then regulates gene transcription, producing estrogenic effects that alleviate menopausal symptoms, support bone density, and restore normal hormonal balance.

The specific dose and patch change interval for Lenzetto are determined by the prescribing clinician based on the individual’s clinical condition, age, and response to therapy. Patients should follow the prescriber’s instructions and not alter the dosing schedule on their own.

Lenzetto is classified as pregnancy category X, meaning it is contraindicated during pregnancy because estrogen can harm the developing fetus. It is also not recommended for breastfeeding women, as estradiol may pass into breast milk and affect the infant.

To order Lenzetto, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with oral estrogen tablets, the transdermal patch delivers estradiol directly through the skin, bypassing first‑pass hepatic metabolism. This can result in more stable serum levels and a lower impact on liver‑produced clotting factors, potentially reducing the risk of certain cardiovascular side effects.

Lenzetto patches should be stored at room temperature, protected from light and moisture, and kept in their original packaging. Do not expose the patches to temperatures above 30 °C or to direct sunlight, as extreme conditions may affect drug potency.

Lenzetto is applied to clean, dry, intact skin on the lower abdomen, buttock, or upper arm. The patch is typically worn for a week and then replaced with a new one at the same time each week. Patients should rotate application sites to minimize skin irritation.

Serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, stroke, gallbladder disease, and possible progression of estrogen‑dependent cancers (breast or endometrial). Patients should seek immediate medical attention if they experience sudden leg pain, shortness of breath, severe headache, or abnormal vaginal bleeding.

Lenzetto should not be used by women with known estrogen‑dependent tumors, active breast cancer, a history of thromboembolic disorders, uncontrolled hypertension, severe liver disease, or those who are pregnant or breastfeeding. It is also contraindicated in individuals with unexplained vaginal bleeding.